Literature DB >> 15223136

Estrogen and progesterone receptors in ovarian epithelial tumors.

Peter R Lindgren1, Stefan Cajander, Torbjörn Bäckström, Jan-Ake Gustafsson, Sari Mäkelä, Jan I Olofsson.   

Abstract

Epidemiological studies have indicated a relationship between ovarian cancer and gonadal steroid hormones. In the present study immunohistochemical localization in combination with morphometry were used to characterize changes in the pattern of expression for estrogen receptor alpha (ERalpha), estrogen receptor beta (ERbeta), and progesterone receptor (PR), in epithelial cells of normal ovaries, and in benign, borderline and malignant ovarian tumors of different types (n=53). Positive correlations with immunoreactivity of the cell proliferation-marker, Ki67, and the apoptosis-related marker of genetic instability, p53, between the different tumor types were also found. A simultaneous expression of ERalpha, ERbeta and PR in epithelial cells of all histopathological tumor types was noted, with the notable exception of all mucinous tumors who remained ERbeta-positive, but ERalpha- and PR-negative. Epithelial cells in ovarian cancer tissue showed significantly lower mean immunoreactivity of ERbeta and PR, but not ERalpha, than in normal ovarian tissue. These novel findings may provide a rationale for the development of new diagnostic and possibly therapeutic strategies.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15223136     DOI: 10.1016/j.mce.2004.02.020

Source DB:  PubMed          Journal:  Mol Cell Endocrinol        ISSN: 0303-7207            Impact factor:   4.102


  21 in total

Review 1.  Estrogen receptor beta, a possible tumor suppressor involved in ovarian carcinogenesis.

Authors:  Gwendal Lazennec
Journal:  Cancer Lett       Date:  2006-01-18       Impact factor: 8.679

2.  Estrogen and progesterone receptor status and outcome in epithelial ovarian cancers and low malignant potential tumors.

Authors:  Hugo Arias-Pulido; Harriet O Smith; Nancy E Joste; Therese Bocklage; Clifford R Qualls; Allison Chavez; Eric R Prossnitz; Claire F Verschraegen
Journal:  Gynecol Oncol       Date:  2009-06-27       Impact factor: 5.482

Review 3.  Molecular targeted therapy in ovarian cancer: what is on the horizon?

Authors:  Roshni Kalachand; Bryan T Hennessy; Maurie Markman
Journal:  Drugs       Date:  2011-05-28       Impact factor: 9.546

4.  Hormonal Maintenance Therapy for Women With Low-Grade Serous Cancer of the Ovary or Peritoneum.

Authors:  David M Gershenson; Diane C Bodurka; Robert L Coleman; Karen H Lu; Anais Malpica; Charlotte C Sun
Journal:  J Clin Oncol       Date:  2017-02-21       Impact factor: 44.544

Review 5.  New insights on the role of hormonal therapy in ovarian cancer.

Authors:  Fiona Simpkins; Arlene Garcia-Soto; Joyce Slingerland
Journal:  Steroids       Date:  2013-02-08       Impact factor: 2.668

6.  Survival of women with ovarian carcinomas and borderline tumors is not affected by estrogen and progesterone receptor status.

Authors:  Luis Felipe Sallum; Luis Otavio Sarian; Liliana Lucci De Angelo Andrade; José Vassallo; Fernando Augusto Soares; Glauce Aparecida Pinto; Patrícia Andréia Ferreira; Sophie Derchain
Journal:  J Gynecol Oncol       Date:  2013-04-05       Impact factor: 4.401

7.  The prognostic value of estrogen receptor beta and proline-, glutamic acid- and leucine-rich protein 1 (PELP1) expression in ovarian cancer.

Authors:  Stefanie Aust; Peter Horak; Dietmar Pils; Sophie Pils; Christoph Grimm; Reinhard Horvat; Dan Tong; Bernd Schmid; Paul Speiser; Alexander Reinthaller; Stephan Polterauer
Journal:  BMC Cancer       Date:  2013-03-14       Impact factor: 4.430

8.  Estrogen receptor alpha expression in ovarian cancer predicts longer overall survival.

Authors:  Agnieszka Halon; Verena Materna; Malgorzata Drag-Zalesinska; Ewa Nowak-Markwitz; Tserenchunt Gansukh; Piotr Donizy; Marek Spaczynski; Maciej Zabel; Manfred Dietel; Hermann Lage; Pawel Surowiak
Journal:  Pathol Oncol Res       Date:  2011-01-06       Impact factor: 3.201

9.  Estrogen receptor beta rs1271572 polymorphism and invasive ovarian carcinoma risk: pooled analysis within the Ovarian Cancer Association Consortium.

Authors:  Galina Lurie; Lynne R Wilkens; Pamela J Thompson; Yurii B Shvetsov; Rayna K Matsuno; Michael E Carney; Rachel T Palmieri; Anna H Wu; Malcolm C Pike; Celeste L Pearce; Usha Menon; Aleksandra Gentry-Maharaj; Simon A Gayther; Susan J Ramus; Alice S Whittemore; Valerie McGuire; Weiva Sieh; Paul D P Pharoah; Honglin Song; Jacek Gronwald; Anna Jakubowska; Cezary Cybulski; Jan Lubinski; Joellen M Schildkraut; Andrew Berchuck; Susanne Krüger Kjær; Estrid Høgdall; Peter A Fasching; Matthias W Beckmann; Arif B Ekici; Alexander Hein; Georgia Chenevix-Trench; Penelope M Webb; Jonathan Beesley; Marc T Goodman
Journal:  PLoS One       Date:  2011-06-06       Impact factor: 3.240

Review 10.  Primary and recurrent serous borderline tumors during pregnancy: a case report and literature review.

Authors:  Aya Matsumoto; Takuma Ito; Fumika Hamaguchi; Maya Kasuga; Teppei Mikami; Mayo Hino; Reiko Yokoyama; Shogo Yamamura; Harumi Sakata; Sachiko Minamiguchi; Masaki Mandai; Takaaki Yoshida
Journal:  Int Cancer Conf J       Date:  2021-02-26
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.